Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
4
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
4
×
national
national blog main
national top stories
4
×
new york blog main
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
4
×
wisconsin blog main
wisconsin top stories
startups
accent therapeutics
aducanumab
alexion pharmaceuticals
alzheimer's disease
asklepios biopharmaceutical
biogen
bridgebio
bristol-myers squibb
cancer immunotherapy
cell therapy
What
bio
new
4
×
roundup
4
×
drug
activity
advantages
approval
approvals
bails
bar
biogen
biogen’s
biopharmaceutical
brand
bridgebio
brings
capital
car
clamped
companies
convo
covid
delays
develop
developing
drugs
earlier
economic
emerges
expect
failures
fast
fda
firm
gamble
grab
headlines
ichnos
including
invest
Language
unset
Current search:
new
×
cancer
×
" life sciences "
×
" texas top stories "
×
" national top stories "
×
roundup
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More